ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

Pharma services firm Sygnature acquires DMPK specialist XenoGesis

by Michael McCoy
October 2, 2020 | APPEARED IN VOLUME 98, ISSUE 38

 

The British contract research firm Sygnature has acquired XenoGesis, which it calls the UK’s largest independent company specializing in drug metabolism and pharmacokinetics. Both firms are based in the BioCity complex in Nottingham, England. Sygnature says the deal continues a push beyond its roots in pharmaceutical chemistry services. In recent years it has purchased the in vivo pharmacology providers RenaSci and Alderley Oncology.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment